CytoDyn Inc. (CYDY)
OTCMKTS · Delayed Price · Currency is USD
0.2220
-0.0068 (-2.97%)
At close: Nov 20, 2026
CytoDyn Company Description
CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications.
The company develops leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19.
Its leronlimab completed phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer.
The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
CytoDyn Inc.

| Country | United States |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Robert Hoffman |
Contact Details
Address: 1111 Main Street Vancouver, Washington 98660 United States | |
| Phone | 360 980 8524 |
| Website | cytodyn.com |
Stock Details
| Ticker Symbol | CYDY |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | June - May |
| Reporting Currency | USD |
| ISIN Number | US23283M1018 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Robert E. Hoffman B.B.A., C.P.A. | Chief Executive Officer and Principal Accounting Officer |
| Tyler Blok | Chief Legal Officer and Corporate Secretary |
| Dr. Jacob P. Lalezari M.D. | Head of Research and Translational Sciences |